PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.90
Current Ratio 0.5–0.75x Medical - Pharmaceuticals median of 1.57. Guy Spier would worry about potential short-term pinch.
0.45
Quick Ratio below 0.5x Medical - Pharmaceuticals median of 1.13. Jim Chanos might see a liquidity gap if the firm cannot tap more credit swiftly.
0.38
Cash Ratio 0.75–0.9x Medical - Pharmaceuticals median of 0.44. John Neff could push for improved balance sheet strength.
46.19
Interest coverage of 46.19 versus zero Medical - Pharmaceuticals median. Walter Schloss would verify if our debt service capacity provides advantages.
2.59
Short-term coverage of 2.59 versus zero Medical - Pharmaceuticals median. Walter Schloss would verify if our cash flow management provides advantages.